Octreotide Acetate interactions

Food & lifestyle

• food

  Moderate

  Absorption

  Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications. Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat.

  What to do: Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs. Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.

  5 sources

  1. Landgraf R, Landgraf-Leurs MM, Nusser J, et al. "Effect of somatostatin analogue (SMS201-995) on cyclosporine levels." Transplantation 44 (1987): 724-5
  2. Ho PJ, Boyajy LD, Greenstein E, Barkan AL "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci 38 (1993): 309-15
  3. Katz MD, Erstad BL "Octreotide, a new somatostatin analogue." Clin Pharm 8 (1989): 255-73
  4. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):
  5. "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc (2007):

Conditions

Conditions in which Octreotide Acetate needs care, as documented in this source.

• Kidney Diseases

  Major

  Octreotide is eliminated by the kidney. Approximately 30% of octreotide is excreted unchanged in the urine. The serum concentration of octreotide and the half-life is increased in patients with severe renal dysfunction. Therapy with octreotide should be administered cautiously and dosage modification considered in patients with severe renal impairment as the half-life of octreotide may be increased, necessitating adjustment of the dosage.

  1 source

  1. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):

• Gallbladder Diseases

  Moderate

  Octreotide inhibits gallbladder contractility and may alter bile composition. An average of 29% of patients develop new gallstones during octreotide therapy, and up to 20% of patients develop biliary sludge. Associated pancreatitis has been reported in rare cases. Gallbladder hypercontractility, sometimes resulting in biliary colic, has been reported upon withdrawal of octreotide.

  14 sources

  1. Catnach SM, Wass JA, Anderson JV, Besser M, Fairclough P, Hussaini H, Dowling H "Gall stones induced by octreotide." BMJ 305 (1992): 313
  2. Shi YF, Zhu XF, Harris AG, Zhang JX, Dai Q "Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients." J Clin Endocrinol Metab 76 (1993): 32-7
  3. Sadoul JL, Benchimol D, Thyss A, Freychet P "Side-effects of octreotide withdrawal." Lancet 339 (1992): 376
  4. James RA, Rhodes M, Rose P, Kendall-Taylor P "Biliary colic on abrupt withdrawal of octreotide." Lancet 338 (1991): 1527
  5. Baxter JN, Imrie CW, McKay CJ "Acute pancreatitis and octreotide." Lancet 338 (1991): 389
  6. Fredenrich A, Sosset C, Bernard JL, Sadoul JL, Freychet P "Acute pancreatitis after short-term octreotide." Lancet 338 (1991): 52-3
  7. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JA "Gallstones during octreotide therapy." Metabolism 41(9 Suppl) (1992): 22-33
  8. Gradon JD, Schulman RH, Chapnick EK, Sepkowitz DV "Octreotide-induced acute pancreatitis in a patient with acquired immunodeficiency syndrome." South Med J 84 (1991): 1410-1

  Show all 14 sourcesShow fewer sources

  9. Dowling RH, Hussaini SH, Murphy GM, Wass JA "Gallstones during octreotide therapy." Digestion 55 Suppl 1 (1993): 107-20
  10. Ahrendt SA, McGuire GE, Pitt HA, Lillemoe KD "Why does somatostatin cause gallstones?" Am J Surg 161 (1991): 177-82;disc. 182-3
  11. Daughaday WH "Octreotide is effective in acromegaly but often results in cholelithiasis." Ann Intern Med 112 (1990): 159-60
  12. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):
  13. Redfern JS, Fortuner WJ "Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management." Am J Gastroenterol 90 (1995): 1042-52
  14. Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, Wass JAH, Dowling RH "Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones." Gut 38 (1996): 775-83

• Glucose Intolerance

  Moderate

  The incidence of hypoglycemia may increase during octreotide therapy due to inhibition of glucagon and growth hormone. Hyper- and hypoglycemia have been associated with the use of octreotide in nondiabetic patients with acromegaly. Clinical monitoring of blood glucose is recommended in patients with diabetes or insulinoma.

  7 sources

  1. McKnight JA, McCance DR, Crothers JG, Atkinson AB "Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly." BMJ 299 (1989): 604-5
  2. Osei K, O'Dorisio TM, Malarkey WB, Craig EL, Cataland S "Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy." Diabetes 38 (1989): 704-9
  3. Abrahamson MJ "Death from diabetic ketoacidosis after cessation of octreotide in acromegaly." Lancet 336 (1990): 318-9
  4. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):
  5. Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M "Long-term effect of octreotide in acromegaly on insulin resistance." Horm Metab Res 27 (1995): 226-30
  6. Gama R, Marks V, Wright J, Teale JD "Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon." Clin Endocrinol (Oxf) 43 (1995): 117-20
  7. Lamberts SWJ, Vanderlely AJ, Deherder WW, Hofland LJ "Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon - commentary." Clin Endocrinol (Oxf) 43 (1995): 120-2

• Heart Diseases

  Moderate

  Bradycardia, arrhythmias and conduction abnormalities, including QT prolongation have been reported with the use of octreotide. Patients taking other drugs that have bradycardic effects may need dose adjustments. Caution is recommended in patients with cardiac function abnormalities.

  1 source

  1. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):

• Hepatic Insufficiency

  Moderate

  The half-life of octreotide may be increased in patients with liver cirrhosis, necessitating adjustment of dosage. This dose should be up titrated based on clinical response and speed of response as deemed necessary by the physician.

  1 source

  1. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):

• Hypothyroidism

  Moderate

  Rarely, hypothyroidism requiring thyroid hormone replacement may occur during chronic therapy. More commonly, a statistically significant, but usually clinically insignificant, increase in TSH may be observed, possibly caused by slight inhibition of peripheral deiodination of thyroxin. Therapy with octreotide should be administered cautiously to patients with uncontrolled thyroid disorders. Clinical monitoring of thyroid function is recommended.

  2 sources

  1. Christensen SE, Weeke J, Kaal A, Harris AG, Orskov H "SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects." Horm Metab Res 24 (1992): 237-9
  2. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):

• Vitamin B 12 Deficiency

  Moderate

  Decreased serum concentrations of vitamin B12 have occurred during chronic administration of octreotide. Therapy with octreotide should be administered cautiously to patients with uncontrolled vitamin B12 deficiency.

  1 source

  1. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation (2001):